Hanall Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Hanall Biopharma has a total shareholder equity of ₩171.4B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩212.9B and ₩41.6B respectively.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | n/a |
| Cash | ₩27.22b |
| Equity | ₩171.36b |
| Total liabilities | ₩41.56b |
| Total assets | ₩212.92b |
Recent financial health updates
No updates
Recent updates
Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up
Oct 14
Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)
Jun 26Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely
May 22There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings
Mar 13Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years
Feb 12What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?
Jan 25
Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 04Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?
Dec 14Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching
Nov 21Financial Position Analysis
Short Term Liabilities: A009420's short term assets (₩86.1B) exceed its short term liabilities (₩30.1B).
Long Term Liabilities: A009420's short term assets (₩86.1B) exceed its long term liabilities (₩11.5B).
Debt to Equity History and Analysis
Debt Level: A009420 is debt free.
Reducing Debt: A009420 had no debt 5 years ago.
Debt Coverage: A009420 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A009420 has no debt, therefore coverage of interest payments is not a concern.